Kaneka Launches WaveSelect Guidewire, Targeting U.S. Neurovascular Market

NEW YORK, NY – January 13, 2026 – Kaneka Medical America LLC today announced a significant expansion of its neurovascular portfolio with the U.S. launch of the WaveSelect™ 1014 guidewire. The launch, made possible through an exclusive distribution agreement with the global med-tech firm Enlight Medical Ltd., introduces a next-generation access tool designed to improve precision and performance in delicate neurovascular interventions.

The move signals Kaneka's deepening commitment to the U.S. neurovascular market, a sector experiencing rapid growth driven by an increasing preference for minimally invasive surgical techniques. By adding WaveSelect, a device with a proven track record in Asia, Kaneka aims to provide American surgeons with a more versatile and reliable tool for treating complex conditions like brain aneurysms and ischemic strokes.

A Leap in Guidewire Precision and Performance

At the heart of the WaveSelect 1014 is its proprietary polymer-metal matrix technology, an innovation originally engineered in Japan. Unlike conventional guidewires where a gap exists between the inner core wire and the outer coil, WaveSelect's design integrates these components with a flexible polymer fill. This seemingly simple change has profound implications for procedural performance.

The integrated structure provides exceptional torque transmission, allowing surgeons to translate minute movements at their end of the wire into precise, one-to-one responses at the distal tip, deep within the brain's tortuous vascular network. This radical responsiveness is critical when navigating complex anatomical pathways to reach a treatment site.

Furthermore, the polymer-metal matrix technology delivers what many clinicians find to be a critical advantage: superior tip shape retention. Surgeons often pre-shape the tip of a guidewire to navigate specific vessel bifurcations. Traditional wires can lose this shape after a few passes, requiring them to be removed, reshaped, or replaced, thereby extending procedure times and increasing risks. The WaveSelect wire is engineered to maintain its custom shape throughout a complex case.

"Prior to WaveSelect I likely would have used multiple competitive wires for this tortuous vessels case, but I only had to use a single WaveSelect due to its impressive shape retention," commented one leading interventional neurologist from a major U.S. medical center who has evaluated the technology.

With a flexible 0.010-inch distal tip and a more supportive 0.014-inch proximal shaft, the 200 cm wire is designed for both safety and efficacy. Its construction provides the delicate touch needed to avoid vessel perforation while offering the robust support required to deliver microcatheters and therapeutic devices, such as Kaneka's own line of embolization coils.

A Strategic Play in a Growing Market

The launch is a calculated strategic move by Kaneka to capture a larger share of the burgeoning neurovascular device market. The global market for neurovascular guidewires alone was valued at over $330 million in 2023 and is projected to exceed $500 million by 2033, driven by technological advancements and the rising prevalence of cerebrovascular diseases.

By incorporating WaveSelect's "powerful access technology," Kaneka strengthens its existing product line. The company is already known for its embolization coil technology, and the WaveSelect guidewire serves as a direct complement, facilitating the delivery of these life-saving devices.

Ken Toda, President of Kaneka Medical America, highlighted this synergy in the company's announcement. “WaveSelect will complement and strengthen our existing neurovascular portfolio, giving us the opportunity to offer a broader spectrum of solutions to patients suffering from neurovascular disease,” he stated.

This partnership-driven approach allows Kaneka to rapidly introduce cutting-edge technology without the lengthy timeline of in-house development. Rob Abrams, Chief Strategy Officer for Kaneka Medical America, described the alliance with Enlight Medical as "highly synergistic," noting that it aligns not only on a business and clinical level but also with Kaneka’s corporate culture and long-term values. The collaboration underscores a broader industry trend of leveraging external innovation to accelerate market entry and address unmet clinical needs more effectively.

Global Innovation Delivers Local Impact

The story of the WaveSelect guidewire is one of international collaboration. The technology's design originated in Japan, was refined and manufactured by Enlight Medical—a company founded in the U.S. and now headquartered in China with global R&D centers—and is now being brought to American patients by Kaneka, a subsidiary of a Japanese multinational corporation.

Enlight Medical brings a wealth of diverse experience to the partnership. While the WaveSelect is an intravascular device, the company's expertise spans interventional devices for structural heart disease, peripheral artery disease, and even advanced neuromodulation technologies like deep brain stimulation (DBS) and brain-computer interfaces (BCIs). This broad R&D focus, with centers in Boston, San Francisco, and across China, positions Enlight as a formidable innovator in the medical technology space.

Before its U.S. debut, the WaveSelect guidewire has already been used in over 40,000 clinical cases across Japan and China, building a substantial body of real-world evidence supporting its performance and reliability. This extensive clinical history helped pave the way for its entry into the American market, which was officially sanctioned by a Premarket Notification (510(k)) clearance from the U.S. Food and Drug Administration.

For American neurosurgeons and interventional neurologists, the availability of the WaveSelect 1014 offers a new option for tackling their most challenging cases. The wire's unique combination of flexibility, support, and durable responsiveness has the potential to enhance procedural efficiency, reduce complications, and ultimately improve outcomes for patients undergoing minimally invasive treatments for life-threatening neurovascular conditions.